Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Green energy technology objectives risk being missed if supply fails to meet demand, says GlobalData

Green energy technologies are in demand worldwide. Over 70 countries have set net-zero targets, and even more have pledged to lower their emissions. However, ambitious objectives to scale up green energy sources such as solar, wind, and nuclear are straining natural resources, particularly the minerals required to produce these essential technologies. With more than 50 […]
Read more

Precision fermentation pivotal in evolution of Malaysia’s dairy alternatives market, opines GlobalData

Plant-based dairy drinks alternatives, particularly soy, oat, and almond milk, have gained considerable popularity among Malaysians in recent years due to their health benefits. However, the category’s mainstream penetration is being constrained by deficiencies in flavor, texture, and aroma, and high product prices. New technologies such as precision fermentation are thereby pivotal for catalyzing the […]
Read more

Soliris approval for MG will allow AstraZeneca play key role in rare disease treatment ecosystem in China, says GlobalData

AstraZeneca’s Soliris (eculizumab) was approved in China in June 2023 for the treatment of adults with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive. MG patients in China will now finally have access to this novel targeted therapy as part of an expanded treatment algorithm. This will allow AstraZeneca to play a […]
Read more

Inflation law drives biologic drugs to outpace small molecules in venture financing in US, finds GlobalData

Biotechs located in the US received 19% or $7.6 billion more venture financing from 2018-2023 (YTD) for biologic innovator drugs compared to small molecule innovator drugs, driven by the enactment of the inflation law in the country to drive down prescription drug prices, reveals GlobalData, a leading data and analytics company. According to GlobalData’s Pharma […]
Read more

Local ingredient sourcing key for plant-based proteins to attain price parity with animal meat in Malaysia, opines GlobalData

Pricing has become a major pain point for plant-based meat alternatives in light of the cost of living crisis over the past year. Localized production and ingredient sourcing are potential pathways for plant-based protein companies to rationalize product costs. Going forward, price parity will be a key factor in bolstering the growth of the Malaysian […]
Read more

APAC connected vehicle technologies market to register CAGR of 4.9% over 2021-26, forecasts GlobalData

The Asia-Pacific (APAC) region is set to witness a revolution in the automotive industry as connected vehicles continue to gain momentum and reshape the way people travel. With technological advancements, policy support, and evolving consumer preferences, the outlook for connected vehicles in the region appears immensely promising. Against this backdrop, the connected vehicle technologies market […]
Read more

Inflammatory bowel disease treatments reach inflection point requiring active comparators, says GlobalData

At Digestive Disease Week (DDW) 2023, a comment was made following a presentation discussing the preliminary induction findings from QUASAR (NCT04033445), the Phase IIb/III trial evaluating Janssen’s guselkumab (GUS) in ulcerative colitis (UC). A member of the audience questioned the talk’s overall conclusion that GUS is a “great therapy”. This individual’s comment reflects an overarching […]
Read more

P&G taps Lazada to capitalize on growing demand for personalized haircare solutions in Southeast Asia, says GlobalData

Procter & Gamble (P&G), a multinational consumer goods company, recently announced its partnership with Lazada, one of Southeast Asia’s major e-commerce platforms, to launch #HairDNA, a haircare microsite for consumers, in the region. The initiative is aimed at tapping the growing demand from young consumers for personalized haircare solutions in Southeast Asia, according to GlobalData, […]
Read more

Rystiggo will need excellent marketing strategy to fully compete in myasthenia gravis space, says GlobalData

The FDA has recently approved UCB’s subcutaneous formulation of rozanolixizumab-noli, branded as Rystiggo, for use in myasthenia gravis (MG). The approval of Rystiggo comes six months after the FDA accepted UCB’s priority review application, making it the first approved treatment for MG. It is indicated for both anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK) […]
Read more
1 … 108 109 110 111 112 … 136